Hengrui Pharma(SH:600276) CSC SECURITIES (HK) LTD·2025-08-21 07:47Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [6][11]. Core Insights - The company reported a revenue of RMB 15.76 billion for H1 2025, representing a year-over-year increase of 15.9%, and a net profit of RMB 4.45 billion, up 29.7% year-over-year [7]. - The growth in net profit is attributed to both innovative drug sales and significant licensing income from Merck Sharp & Dohme and IDEAYA, totaling USD 2 billion and USD 75 million respectively [7]. - The company has launched an employee stock ownership plan and a share buyback plan, which are expected to enhance innovation and drive performance [7]. Company Performance - The company achieved a net profit of RMB 4.45 billion in H1 2025, with a year-over-year growth of 29.7% [7]. - The revenue from innovative drugs reached RMB 7.57 billion, marking a 14.5% increase year-over-year [7]. - The company expects to continue benefiting from business development (BD) transactions, which are projected to further enhance net profit in the second half of the year [7]. Financial Projections - The company forecasts net profits of RMB 10.1 billion, RMB 8.75 billion, and RMB 10.4 billion for 2025, 2026, and 2027 respectively, with year-over-year growth rates of 59.3%, -13.3%, and 18.9% [7][10]. - Earnings per share (EPS) are projected to be RMB 1.52, RMB 1.32, and RMB 1.57 for the same years [10]. Shareholder Information - The major shareholder is Jiangsu Hengrui Medicine Group Co., Ltd., holding 23.18% of the shares [7]. - Institutional investors hold 9.1% of the circulating A-shares, while general corporations hold 68.1% [3]. Market Position - The company operates primarily in the pharmaceutical and biotechnology sector, with a product mix that includes 52.1% from oncology, 15.3% from neuroscience, and 9.8% from contrast agents [2]. Stock Performance - The stock price as of August 20, 2025, was RMB 62.85, with a target price set at RMB 75.4, indicating a potential upside [6]. - The stock has shown a year-over-year increase of 49.8% [6].